Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Sebia partners with Inserm Transfert to develop a unique diagnostic test for haemoglobin diseases

06.06.2012
This collaboration will focus mainly on the diagnosis of thalassaemias with the aim of commercializing a simple and quick new test
Sebia, a world leader in the electrophoresis of proteins used to diagnose a large number of pathologies, announces today that it has entered into partnership with Inserm (the French National Institute of Health and Medical Research) and Inserm Transfert, its private subsidiary responsible for marketing the outcomes of its scientific research, to develop and commercialize a unique biological test for measuring free alpha globin chains in beta-thalassaemic patients. The test will indicate the severity index of the disease in patients.

Negotiated by Inserm Transfert, the collaboration calls for Sebia to support the research carried out by Inserm, which will develop the test. In return, Sebia will have the possibility of acquiring exclusive rights to industrially develop and commercialize the test internationally.

“By teaming up with Inserm, Sebia is strengthening its commitment to the research and development of tools for diagnosing haemoglobinopathies and monitoring their treatment,” said Benoît Adelus, President and CEO of Sebia. “This test is an important innovation. It will complement the solutions currently offered by Sebia, which are designed to improve the diagnosis and treatment of these haemoglobinopathies.”

“We were looking for a company that was interested in developing this test, and the choice fell quite naturally to Sebia, since we have known the company for a long time and its interest in researching diagnostic tools for haemoglobinopathies,” explained Véronique Baudin-Creuza, from Inserm unit U779 at the University of Paris-Sud 11 and the unit for protein polymerization pathologies, blood substitutes and rare red blood cell diseases at Bicêtre Hospital.

The test for quantifying alpha globin chains was developed by unit U779 along with the participation of the research team of Professor Frédéric Galactéros, who heads the red blood cell genetic disease unit at the Henri Mondor Hospital within the Paris Public Hospital Authority. According to Prof. Galactéros, the test Sebia and Inserm Transfert will develop will fill a gap in orienting the diagnosis of thalassaemic patients, since existing methods are more laborious, more costly, and are exclusively intended for research laboratories. Thus, it should result in the commercialization of a new test that does not use radioactivity, will provide a better appreciation of patients’ phenotypes, and will be better adapted to the monitoring of treatment. Furthermore, it will be suitable on a routine basis and available to all laboratories.

“This test provides an immediate indication of the severity of the disease, since the results can be available within a day, whereas it took a week with the old methods,” said Kamran Moradkhani, an associate practitioner at Henri Mondor-Chenevier Hospital. “It ensures that diagnosis is oriented towards identifying the different mutations at work and gives us highly relevant indicators for comparing different groups of patients.”

The test is based on the interaction of the free alpha globin chain with the alpha haemoglobin stabilizing protein (AHSP). In the case of beta-thalassaemias, there is a synthesis deficit in the beta chain, which has the effect of reducing the amount of haemoglobin A (HbA) in red blood cells and leading to an imbalance between the numbers of alpha and beta chains. This imbalance leads to a relative excess of alpha chains. These chains are very unstable, and despite the fact that the AHSP plays the role of chaperone (capable of controlling and stabilizing them), in people suffering from beta-thalassaemias, they form precipitates that act like oxidants and damage the cell, resulting in apoptosis (cell death) and inefficient erythropoiesis (cell production).

According to the size of the pool of free alpha chains, one can determine the severity of the disease in thalassaemia patients, but also in patients with a synthesis imbalance in their globin chains.

A preliminary study of this test has been carried out on 54 subjects (consisting of 20 patients suffering from beta-thalassaemia, 6 patients with alpha-thalassaemia, and a 28-reference control group). The phenotypes of the different haemoglobins were studied using high-performance liquid chromatography (HPLC) methods. This technique ensures an accurate measurement of foetal haemoglobin (HbF) and HbA2, the percentage of which is an important element for the diagnosis of thalassaemias. “HPLC and capillary electrophoresis separation techniques are valuable tools for identifying or confirming the presence of abnormal haemoglobins,” explains Véronique Baudin-Creuza.
Sebia brought together a panel of world experts at its offices on 25 May to present the test to them so they could assess its relevance. The meeting was chaired by Professor Andrea Mosca, of the Department of Biomedical Sciences and Technologies (CIRME) at the University of Milan, Italy, who declared that the test was “of real interest for improving the monitoring of patients and their treatment, since determining the free alpha globin chain makes it possible to highlight the onset of serious complications linked to these very heterogeneous haemoglobinopathies.”

Another study of the test will be conducted on 100 patients in 2013 and will be carried out by the same research team.
About Thalassaemias
Thalassaemia is the result of a deficit synthesis in one of the haemoglobin chains. Haemoglobin A (HbA) includes polypeptide chains that are alpha and beta. Normally, HbA haemoglobins (alpha 2 and beta 2), HbA2 haemoglobins (alpha 2 delta 2) and HbF foetal haemoglobin (alpha 2 gamma 2) are present in every individual’s blood. In the case of thalassaemia, one observes either deletions (which is to say modifications involving the loss, absence, disappearance or amputation of a segment of chromosome), or thalassaemic variants. In both cases, this leads to an absence or a diminution in the synthesis of haemoglobin chains, which is at the root of what is called inefficient erythropoiesis (the red blood cell production line), associated with a greater or lesser degree of haemolysis (the breakup of red globules). The resulting symptoms are variable, ranging from the asymptomatic form to the major form accompanied by anaemia, an increase in spleen volume, and development troubles.

These pathologies are mainly found in people living in the Mediterranean basin, Asia and Africa.

About Sebia
Sebia develops, manufactures and commercializes protein electrophoresis tests and analyzers for the in vitro diagnosis of certain cancers, inflammatory diseases, metabolic disorders and haemoglobin abnormalities. Sebia’s know-how in electrophoresis techniques enables it to maintain a sustained research and development program, giving all types of laboratories access to real solutions. Its agarose gel product line (Hydragel assays, Assist and Hydrasys 2 instruments chain), capillary assays and their dedicated instruments (Capillarys 2 Flex Piercing, Capillarys 2 Neonat Fast, Minicap Flex Piercing) are designed to be integrated in the same workflow.

Today, Capillarys 2 Flex Piercing is the most advanced instrument in the field of capillary technology, which offers a high level of performance and optimization at the analytical stage. Tests are available for analyzing serum proteins, urinary proteins and immunotyping, for measuring CDT (marker of chronic alcohol abuse), and for screening haemoglobinopathies in the whole blood, with the primary capped tubes. Sebia recently adapted this potent technology to the field of diabetes in order to meet the world’s growing demand for more accurate and reproducible methods to measure HbA1c.

For further information, go to : http://www.sebia.com

About Inserm Transfert
Inserm Transfert SA is a legally incorporated subsidiary of Inserm, the French National Institute of Health and Medical Research, which was created in 2000 to handle the whole process of transferring the knowledge created in Inserm’s research laboratories to industrial companies, from the declaration of the invention to the industrial partnership.
Inserm Transfert also provides services in the mounting and management of large-scale epidemiology and public health projects at the European and International level. Since 2009, it has been managing a portfolio of maturing projects. It also collaborates closely with Inserm Transfert Initiative, the Inserm subsidiary that supports start-ups in the life sciences sector.

http://www.inserm-transfert.com

Press contact:
Céline Cortot – 01 55 03 01 68 ; celine.cortot@inserm-transfert.fr
Lucie Nguyen
ANDREW LLOYD & ASSOCIATES
http://www.ala.com
lucie@ala.com
Follow us on Twitter: https://twitter.com/ALA_Group
55 rue Boissonade 75014 PARIS FRANCE
Tel : +33 1 56 54 07 00 Fax : +33 1 56 54 07 01
Brighton Business Forum 95 Ditchling Road Brighton BN 1 4ST ENGLAND
Tel : +44 1273 675100 Fax : +44 1273 675400
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATIONS

Lucie Nguyen | Andrew Lloyd & Associates
Further information:
http://www.sebia.com

More articles from Health and Medicine:

nachricht Why might reading make myopic?
18.07.2018 | Universitätsklinikum Tübingen

nachricht Unique brain 'fingerprint' can predict drug effectiveness
11.07.2018 | McGill University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Global study of world's beaches shows threat to protected areas

19.07.2018 | Earth Sciences

New creepy, crawly search and rescue robot developed at Ben-Gurion U

19.07.2018 | Power and Electrical Engineering

Metal too 'gummy' to cut? Draw on it with a Sharpie or glue stick, science says

19.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>